ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.
Target:
HER|||Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
